Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial-Reference-Cited by-同舟云学术

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

Published:2014-11 Issue:5 Volume:66 Page:799-802
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Attard Gerhardt,Sydes Matthew R.,Mason Malcolm D.,Clarke Noel W.,Aebersold Daniel,de Bono Johann S.,Dearnaley David P.,Parker Chris C.,Ritchie Alastair W.S.,Russell J. Martin,Thalmann George,Cassoly Estelle,Millman Robin,Matheson David,Schiavone Francesca,Spears Melissa R.,Parmar Mahesh K.B.,James Nicholas D.

Publisher

Elsevier BV

Subject

Urology

Reference12 articles.

1. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial;James;Lancet Oncol,2012

2. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial;Parker;BJU Int,2013

3. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven;Attard;J Clin Oncol,2008

4. Hormonal impact of the 17alphahydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer;O’Donnell;Br J Cancer,2004

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials;The Lancet Oncology;2023-07

2. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol;The Lancet Oncology;2023-05

3. Oligometastatic Prostate Cancer: Current Status and Future Challenges;Journal of Nuclear Medicine;2022-11

4. Accumulation of copy number alterations and clinical progression across advanced prostate cancer;Genome Medicine;2022-09-05

5. Rational Second-Generation Antiandrogen Use in Prostate Cancer;The Oncologist;2022-02-01